157 related articles for article (PubMed ID: 35089801)
1. Discovery and Development of the Quininib Series of Ocular Drugs.
Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
[TBL] [Abstract][Full Text] [Related]
2. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
[TBL] [Abstract][Full Text] [Related]
3. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo.
Galvin O; Srivastava A; Carroll O; Kulkarni R; Dykes S; Vickers S; Dickinson K; Reynolds AL; Kilty C; Redmond G; Jones R; Cheetham S; Pandit A; Kennedy BN
J Control Release; 2016 Jul; 233():198-207. PubMed ID: 27086168
[TBL] [Abstract][Full Text] [Related]
4. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
5. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
[TBL] [Abstract][Full Text] [Related]
6. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
Slater K; Heeran AB; Garcia-Mulero S; Kalirai H; Sanz-Pamplona R; Rahman A; Al-Attar N; Helmi M; O'Connell F; Bosch R; Portela A; Villanueva A; Gallagher WM; Jensen LD; Piulats JM; Coupland SE; O'Sullivan J; Kennedy BN
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066024
[TBL] [Abstract][Full Text] [Related]
7. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
Kennedy SA; Morrissey ME; Dunne MR; O'Connell F; Butler CT; Cathcart MC; Buckley AM; Mehigan BJ; Larkin JO; McCormick P; Kennedy BN; O'Sullivan J
BMC Cancer; 2020 Oct; 20(1):952. PubMed ID: 33008336
[TBL] [Abstract][Full Text] [Related]
8. 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
Slater K; Bosch R; Smith KF; Jahangir CA; Garcia-Mulero S; Rahman A; O'Connell F; Piulats JM; O'Neill V; Horgan N; Coupland SE; O'Sullivan J; Gallagher WM; Villanueva A; Kennedy BN
Front Med (Lausanne); 2022; 9():1036322. PubMed ID: 36698840
[TBL] [Abstract][Full Text] [Related]
9. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
11. Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases.
Rezzola S; Paganini G; Semeraro F; Presta M; Tobia C
Biochim Biophys Acta; 2016 Jul; 1862(7):1291-6. PubMed ID: 27085972
[TBL] [Abstract][Full Text] [Related]
12. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
13. [Research progress of anti-angiogenesis drug targets in diabetic retinopathy].
Wu W; Tang L
Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):871-6. PubMed ID: 25582212
[TBL] [Abstract][Full Text] [Related]
14. 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.
Tonelotto V; Costa-Garcia M; O'Reilly E; Smith KF; Slater K; Dillon ET; Pendino M; Higgins C; Sist P; Bosch R; Passamonti S; Piulats JM; Villanueva A; Tramer F; Vanella L; Carey M; Kennedy BN
Cell Death Discov; 2024 Feb; 10(1):70. PubMed ID: 38341410
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Gong Y; Shao Z; Fu Z; Edin ML; Sun Y; Liegl RG; Wang Z; Liu CH; Burnim SB; Meng SS; Lih FB; SanGiovanni JP; Zeldin DC; Hellström A; Smith LEH
EBioMedicine; 2016 Nov; 13():201-211. PubMed ID: 27720395
[TBL] [Abstract][Full Text] [Related]
16. Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target in Pathological Ocular Angiogenesis.
Nakahara T; Morita A; Yagasaki R; Mori A; Sakamoto K
Biol Pharm Bull; 2017; 40(12):2045-2049. PubMed ID: 29199229
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
Joussen AM
Dtsch Med Wochenschr; 2007 Jun; 132(23):1268-72. PubMed ID: 17541869
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Dong LF; Yao J; Wang XQ; Shan K; Yang H; Yan B; Jiang Q
Biochem Biophys Res Commun; 2015 Oct; 465(4):678-84. PubMed ID: 26255966
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF.
Merrigan SL; Kennedy BN
Br J Pharmacol; 2017 Aug; 174(16):2636-2651. PubMed ID: 28547797
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
